[Université de Montréal] Université de Montréal epidemiologist Vikki Ho has been awarded a $2-million grant over five years to study how environmental and other factors contribute to the onset of colorectal cancer.

[Molecular Cancer] Researchers found that adenosine deaminase tRNA specific 2 (ADAT2)-driven tRNA A-to-I modification promotes colorectal cancer tumorigenesis and chemoresistance via HDAC7-WNT/β-catenin axis.

[Nature Communications] Scientists showed that a conserved axonal guidance cue directs enteroblasts, the immediate intestinal stem cell daughters, to selectively replace worn-out adjacent and remote enterocytes with identical frequency.

[Cancer Research] Investigators identified that the PI3K/mTOR and MAPK/ERK signaling pathways, among other pathways, are linked to the formation of myofibroblast-like cancer-associated fibroblast (CAF) and inflammatory CAF subtypes, respectively.

[NPJ Precision Oncology] Researchers integrated single-cell RNA sequencing, 119,931 cells from 25 gastric tumors, with spatial transcriptomics and bulk cohorts to delineate palmitoylation-linked states across malignant, immune, and stromal compartments.

[NPJ Precision Oncology] The authors analyzed the differentiation trajectory of epithelial cells in different disease stages from gastric antrum biopsies in patients with precancerous lesions and early gastric cancer using single-cell sequencing data.

[Journal of Translational Medicine] Researchers found that cathepsin E drives colorectal cancer progression by stabilizing ZNF326 via ADP-ribosylation and activating TGF-β/SMAD pathway, while facilitating tumor immune evasion.

[Molecular Biomedicine] Investigators delineate the core signaling cascades governing colorectal cancer initiation and progression, with emphasis on the molecular hallmarks of the disease.

[Thomas Jefferson University (Audacy)] The PA Breast Cancer Coalition has awarded two Thomas Jefferson University researchers with $100,000 grants to advance groundbreaking work in triple-negative breast cancer and immunotherapy.

[Cancer Research] Investigators showed that EZH2 inhibitors shift the epigenetic state of human epidermal growth factor receptor 2–positive (HER2+) tumors, dramatically enhancing baseline responses to HER2 kinase inhibitors and resensitizing drug-resistant tumors in vitro and in vivo.

[Cancer Research] Researchers showed that β-hydroxybutyrate levels were markedly decreased in tumor tissues and serum from patients with breast cancer, particularly in metastatic patients.

[AstraZeneca] AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.